The Scientist

Ranbaxy falsified drug data

The generic drug giant Ranbaxy falsified data on shelf life and efficacy on products made in their Paonta Sahib plant in India, the FDA said in a press conference today (Feb.26). In response, the FDA ...
RAPS

DOJ Files 'Groundbreaking' Consent Decree Against Ranbaxy, Company Agrees to 'Remedy Deviations'

The US Department of Justice (DOJ) filed a Consent Decree of Permanent Injunction against Ranbaxy, an Indian generic drug manufacturer, with the US District Court of Maryland on 25 January. The action ...
FierceBiotech

FDA Takes New Regulatory Action Against Ranbaxy's Paonta Sahib Plant in India

The U.S. Food and Drug Administration today announced that a facility owned by India-based Ranbaxy Laboratories falsified data and test results in approved and pending drug applications. The facility, ...
FiercePharma

Ranbaxy Announces Consent Decree with U.S. Food and Drug Administration

GURGAON, India--(BUSINESS WIRE)-- Ranbaxy Laboratories Ltd. (RLL, NSE: RANBAXY, BSE: 500359) (“Ranbaxy”) today announced that it has signed a consent decree with the U.S. Food and Drug Administration ...
RAPS

Do Indian Companies Have a Chronic Data Falsification Problem? FDA Warning Letters Indicate 'Yes'

However, unlike many Warning Letters, which usually cite basic current good manufacturing practice (CGMP) issues, these letters have been altogether far more serious in nature. In fact, FDA has ...